Back to Agenda
Session 10 Track 1 and 2 – Alternative Approaches to Other Extrahepatic Delivery
Session Chair(s)
Andrew Slugg, MBA, MS
Senior Vice President, Global Head of Regulatory Affairs
Alnylam Pharmaceuticals, United States
Elena Braithwaite, PhD
Toxicologist
FDA, United States
Targeted delivery of oligonucleotide-based therapeutics allows for the possibility of unlocking previously inaccessible targets, enhancing target engagement leading to increased therapeutic outcomes with reduced doses and the potential for fewer off-target effects. This session will discuss a number of emerging novel targeting and delivery strategies for increasing productive uptake into a variety of cell types that normally are challenging to reach with oligonucleotide therapeutics.
Learning Objective : At the conclusion of this session, participants should be able to:
- Identify multiple emerging novel targeting strategies for oligonucleotides
- Discuss different strategies for targeting novel cell-types with oligonucleotides
- Contrast the development challenges and opportunities of a variety of emerging novel targeting strategies for oligonucleotides
Speaker(s)
Speaker
Arthur A. Levin, PhD
Avidity Biosciences , United States
CSO
Speaker
Robert MacLeod, PhD
Flamingo Therapeutics, Belgium
Chief Scientific Officer, SVP Research and Development
Speaker
Daniel J. Siegwart, PhD, MS
University of Texas Southwestern Medical Center, United States
Associate Professor, Department of Biochemistry, SCCC
Have an account?